Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

9.730 -0.390 (-3.85%)
Delayed Quote Updated: 2:58 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Absci (ABSI) Q3 2026 Earnings Call Transcript ↗
Pattern hair loss data is due in December as the company expands into endometriosis. 
Via The Motley Fool
Topics Earnings
News headline image
Absci Q3 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company’s... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Absci Corp (NASDAQ:ABSI) Q3 2026 Revenue Miss Puts ABS-201 Data and Cash Runway in Focus ↗
Via Chartmill
News headline image
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances ↗
Via Chartmill
News headline image
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp. 
From Wall Street Investor
Via GlobeNewswire
News headline image
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
From Biotech Insider
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci (ABSI) Q2 2026 Earnings Call Transcript ↗
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. 
Via The Motley Fool
Topics Earnings
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
From Absci Corporation
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
From Absci Corporation
Via GlobeNewswire
News headline image
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 ↗
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci (ABSI) Q1 2026 Earnings Call Transcript ↗
Absci (ABSI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.